Platelet transfusion therapy

Journal of Clinical Apheresis

Volumn 16, Issue 1, 2001, Pages 43-48

  Goodnough, Lawrence Tim ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apheresis platelets; Thrombopoietin; Transfusion

Indexed keywords

THROMBOCYTE CONCENTRATE; THROMBOPOIETIN;

BLOOD DONOR; CONFERENCE PAPER; DOSIMETRY; ECONOMIC ASPECT; HUMAN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS;

HUMANS; PLATELET TRANSFUSION;

EID: 0035039271     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/jca.1011     Document Type: Conference Paper

References (36)

1. Collection and transfusion of blood and blood components in the United States, 1994
2. Demand leukocyte-depleted blood for more complete patient protection
3. Frequency of immediate adverse events associated with apheresis donation
4. Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program
5. Blood transfusion and blood conservation: Cost and utilization issues
6. High-yield platelet concentrates attainable by continuous quality improvement reduce platelet transfusion cost and donor exposure
7. Cost effectiveness of reducing donor exposures with single-donor versus random donor platelets
8. Leukocyte-reduction and UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
9. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
10. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
11. 9/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
12. Economic impact of donor platelet count and platelet yield in apheresis products: Relevance for emerging issues in platelet transfusion therapy
13. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronic platelet transfusion dependent patient
14. Effective and efficient platelet increment in patients undergoing hematopoietic progenitor cell transplantation
15. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for fixed platelet requirements
16. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders
17. Clinical consequences of alterations in platelet transfusion dose; a prospective randomized double-blind trial
18. Platelet transfusion: A dose-response study
19. Clinical factors influencing post transfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation
20. Thrombopoietin
21. The thrombocytopenia of cancer: Prospects for effective cytokine therapy
22. A randomized, placebo-controlled trial of recombinant human interleukin-l 1 in cancer patients with severe thrombocytopenia due to chemotherapy
23. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor in patients with advanced cancer
24. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation
25. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer
26. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor [PEG-rHuMGDF] with filgrastim after dose-intensive chemotherapy in patients with advanced cancer
27. Effect of a single dose of pegylated human recombinant megakaryocyte growth and development factor [PEG-rHuMGDF] on platelet counts: Implications for platelet apheresis
28. Pegylated recombinant human megakaryocyte growth and development factor [PEG-rHuMGDF] increases platelet [PLT] count [CT] and apheresis yields of normal platelet donors: Initial results
29. Treatment of platelet donors with pegylated recombinant human megakaryocyte growth and development factor increases circulating platelet counts and platelet apheresis yields and increases platelet increments in recipients of platelet transfusion
30. Platelet collection with the Amicus and the Astec 204 blood cell separator
31. Demographic characteristics, unreported risk behaviors, and the prevalence and incidence of viral infections: A comparison of apheresis and whole blood donors
32. Decreasing platelet concentrate dose: Impact on platelet transfusion interval
33. Photochemical inactivation of viruses and bacteria in paletelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
34. Medical progress: Transfusion medicine. Part I: Blood transfusion